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Abstract
In Hong Kong, the CCR5 antagonist has recently been introduced into salvage therapy for multiclass drug-
resistant HIV-1-infected patients. Coreceptor usage must be determined prior to the usage of the CCR5 antag-
onist, which does not inhibit X4-tropic viruses. This study aimed to determine the tropism prevalence for HIV-1
subtypes B and CRF01_AE in Hong Kong. In addition, a modified promoter-PCR phenotypic assay was used to
validate the genotypic tropism prediction on CRF01_AE. One hundred and five subtype B and 98 CRF01_AE
antiretroviral-naive patients were recruited for this study. The viral env V3 region isolated from the patients was
sequenced and analyzed by Geno2pheno (FPR = 5.75% or 10%, Clonal or Clinical), position-specific scoring
matrix (WebPSSM, x4r5 subtype B matrix), and the combination of 11/25 and net charge rules. Fifteen con-
cordant and 22 discordant tropism genotyped CRF01_AE samples were further phenotyped by either enhanced
sensitivity Trofile assay or an optimized promoter-PCR phenotypic assay. The prevalence of Dual/Mixed- or
X4-tropic virus in antiretroviral-naive subtype CRF01_AE was 39.1%, which was significantly higher than
subtype B ( p < 0.05), regardless of the choices of genotypic algorithms. Our phenotypic data proposed that a
better genotypic tropism prediction for HIV-1 CRF01_AE would be using both Geno2pheno (FPR = 10%, Clonal)
and WebPSSM (x4r5 subtype B matrix) algorithms in combination. The sensitivity and specificity for this
combination were 88.9% and 89.3%, respectively. The comparatively high prevalence of Dual/Mixed- or X4-
tropic virus in CRF01_AE demonstrated the need for special attention to future treatment strategies.
Introduction
HIV-1 uses one or both major chemokine coreceptors,namely CCR5 and CXCR4, for entering host cells.1
This entry pathway can be blocked by the recently devel-
oped CCR5 antagonist, maraviroc (MVC), which has in-
hibitory effects on R5-tropic (R5) viruses only.2 From 2007,
the U.S. Food and Drug Administration and the European
Medicines Agency have approved the use of MVC for
treatment-experienced patients who only have the R5 virus
detected.3 Thus, the determination of viral tropism becomes
crucial and is highly recommended before initiating MVC
treatment.
The Enhanced Sensitivity Trofile Assay (ESTA) (Mono-
gram Biosciences, USA) is believed to be the ‘‘gold standard’’
for HIV tropism phenotypic determination and is available
only in the United States.4–6 Due to its limited accessibility,
other in-house phenotyping assays or genotyping assays have
been developed for coreceptor prediction.7–10 Although the
phenotyping assays provide better sensitivity and specificity,
they are time consuming to process and require intensive
laboratory set-up, which is definitely not suitable for clinical
diagnosis. Hence the use of genotyping methods becomes the
global trend for tropism prediction. Different genotypic al-
gorithms are designed on the basis of the variable loop 3 (V3)
in the HIV-1 env region, which is believed to interact with
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coreceptor when binding.11–13 The simplest prediction rule
relies on the basic amino acids present at positions 11 and/or
25 of the V3 loop and the net charge of the sequences.14 A
modified prediction rule considering both 11/25 and net
charge rules was proposed since it had a better prediction
result for non-B subtypes.15 In addition, Geno2Pheno [cor-
eceptor] (G2P) andposition-specific scoringmatrix (WebPSSM)
are two more advanced interpretation algorithms and
achieved high concordance with phenotyping data in several
clinical studies with HIV-1 subtype B and C isolates. These
algorithms were reported to be around 80–90% specific and
50–60% sensitive for subtype B viruses and a minority of
non-B subtypes.9,12,16–18 On the other hand, less concordance
was observed in other circulating recombinant forms (CRFs)
such as CRF02_AG.19
Several genotypic studies focused on non-B subtypes sug-
gested that subtype CRF01_AE, the major circulating strains
among Southeast Asian countries,20 had a higher proportion
of X4-tropic (X4) or Dual/Mixed-tropic (D/M) than other
subtypes.21–24 However, the small sample size and unknown
treatment background led to many uncertainties in these
studies. In addition, no phenotypic data on CRF01_AE tro-
pism were available to validate any of the above-mentioned
genotypic algorithms. Hence it is critical to investigate and
evaluate the prevalence of X4 or D/M in antiretroviral-naive
patients infected with subtype CRF01_AE.
In this study, we optimized a recently published promoter-
PCR (pPCR) phenotypic assay for CRF01_AE strains and
validated it with the ESTA method.8 The phenotypic tropism
assay was used to compare the genotypic predictions by three
commonly used algorithms. Through the use of the genotypic
tropism results, we tried to study the prevalence of tropism
among subtypes B and CRF01_AE viruses circulating in
Hong Kong.
Materials and Methods
Clinical samples
In 2010 and 2011, there were a total of 827 new HIV-1 in-
fections recorded in Hong Kong.25 About 60% of the patients
sought medical consultation at the Integrated Treatment
Centre (Department of Health, Hong Kong) and 203 anti-
retroviral-naive patients were available for this study. Base-
line peripheral blood was collected from all patients during
their clinic visit at the Centre after consent. An in-house
genotyping assay was used to sequence the HIV-1 pol gene,
which was then analyzed by the REGA Genotyping Tool
version 2.0 for subtype identification.26,27 The tropism of all
samples was first estimated by genotypic tropism prediction.
Based on genotyping, 15 concordant and 22 discordant
CRF01_AE samples were further phenotyped by the ESTA
method and/or the pPCR phenotypic assay.
Genotypic coreceptor prediction
Five hundred microliters of plasma was centrifuged at
20,000· g, 4C for 90min, followed by viral RNA extraction
using the QIAamp Viral RNA Mini Kit according to the
manufacturer’s instructions (Qiagen, Hilden, Germany). The
viral V3 env region was then reverse transcribed and ampli-
fied by the SuperScript III One-Step RT-PCR system with
Platinum Taq High Fidelity enzyme (Invitrogen, USA) in
triplicate.3,28 The 35 amino acid V3 region was nested poly-
merase chain reaction (PCR) by the ExpandHigh Fidelity PCR
system (RocheDiagnostics, Germany) and cycle sequenced by
BigDye Terminator v1.1 (Life Technologies, USA). The am-
plification and sequencing reaction conditions were described
elsewhere.29 All sequences were generated by ABI PRISM
3130xl Genetic Analyzer (Life Technologies, USA) and man-
ually edited by Staden Package version 2.0.30
The HIV-1 tropism was predicted by three sets of algo-
rithms: (1) Geno2Pheno [coreceptor] 1.2 (http://coreceptor
.bioinf.mpi-inf.mpg.de/index.php), the false-positive rate
(FPR) was set at 5.75% or 10%, with or without the input of
viral load andCD4 andCD8 cell counts,9,10 31–33 (2)WebPSSM
(http://indra.mullins.microbiol.washington.edu/webpssm/),
using subtype B x4r5 matrix,12 and (3) the combination of 11/
25 and net charge rules (CN Rules).14
Phenotypic coreceptor prediction by ESTA
(Monogram Biosciences)
Plasma samples of 12 HIV-1 CRF01_AE-infected patients
with viral load above 2,000 copies/ml were randomly se-
lected and sent to Monogram Biosciences in California for
ESTA.
Phenotypic coreceptor prediction by a pPCR
phenotypic assay
A recently published phenotypic assay was adopted in this
study with slight modifications of PCR cycling conditions.8
Briefly, the extracted RNA was reverse transcribed and am-
plified in triplicate reactions. An overlapping PCR technique
was employed to add the CMV promoter/enhancer to the
PCR products without cloning. After cotransfecting pPCR
products and pNL4-3.Luc.R-E-, pseudoviruses produced
were used to infect two U87 indicator cell lines expressing
either the CCR5 or CXCR4 coreceptor. The luciferase activities
were measured to determine coreceptor usage. Reference
viruses, plasmids, and cell lines, including MJ4, LAIBRU, 89.6,
pYU2, pNL4-3, pNL4-3.Luc.R-E-, U87.CD4.CCR5, and
U87.CD4.CXCR4, were obtained from the AIDS Research and
Reference Reagent Program (NIH, USA). MJ4 and LAIBRU
viruses were used as positive controls in each batch of am-
plification and luciferase measurement for R5 and X4 pre-
diction, respectively.
Statistical analyses
The viral loads and CD4 cell counts of subtype B and
CRF01_AE were statically analyzed by two-tailed t-tests
using GraphPad Prism (version 4.0, GraphPad software, CA).
Chi-square tests were used to calculate the tropism genotypic
distributions between subtype B and CRF01_AE. The sensi-
tivity and specificity of each genotypic algorithm were cal-
culated by converting X4 predictions to positive values and
R5 predictions to negative values of the assay.
Results
Characteristics of the patients
After analyzing the pol sequence by REGA, 105 samples
were confirmed to be HIV-1 subtype Bwhile the remaining 98
samples were HIV-1 subtype CRF01_AE. The mean viral load
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and CD4 counts for subtype B treatment-naive patients were
4.77 log10 copies/ml (95% confidence interval: 4.66 to 4.88
log10 copies/ml) and 310 cells/ll (IQR: 163 to 446 cells/ll),
respectively. For subtype CRF01_AE treatment-naive pa-
tients, their mean viral load and CD4 counts were 4.82 log10
copies/ml (95% confidence interval: 4.66 to 4.98 log10 copies/ml)
and 289 cells/ll (IQR: 125–392 cells/ll). Using the t-test,
both subtypes had no significant differences between their
viral load ( p = 0.5907) and CD4 counts ( p= 0.2298).
V3 sequence amplification
Through triplicate PCR amplification reactions, 104 (99.0%)
subtype B and 87 (88.8%) CRF01_AE were successfully se-
quenced and analyzed by Geno2pheno, WebPSSM, and the
CR algorithms. Within the 35 amino acid V3 loop, 11 subtype
B (10.5%) and 11 CRF01_AE (12.6%) samples had variable
lengths of V3 loop. Most of the deletions occurred at position
24, and at other positions such as 6, 18–22, 25, and 27. Inser-
tions were less common and could be found only at positions
15–16 and 19. The length of the V3 loop was proposed to be
related to tropism. For instance, deletion of residues 9 to 12
affects tropism and the extracellular loops of the CXCR4
coreceptor interact more easily with the longer V3 loop.34,35
Yet none of these effects was observed or had an association
with the discordant genotypic coreceptor predictions as
suggested.36
Tropism genotyping by G2P, WebPSSM, and CN Rules
Either the clonal or clinical model and different FPR cut-offs
were selected before inputting V3 sequences into the G2P al-
gorithm. Of the clonal model 5.75% FPR was first selected as
this is the only validated FPR with clinical studies.31,32 ‘‘Re-
commendations from the European Consensus Group on the
clinical management of HIV-1 tropism testing (10% FPR)’’3
was selected for the second batch of analysis. The third set of
analysis used the clinical model of G2P (FPR = 10%)10,33 with
the input of patient clinical parameters including viral load
and CD4 and CD8 cell counts. However, the WebPSSM al-
gorithm uses V3 amino acid sequences for prediction. All
possible amino acid sequences were generated whenever a
heterogeneous viral population was presented. This implied
that more than one prediction would be produced with a
single sequence. D/Mwas assigned if both CCR5 and CXCR4
coreceptor usage was predicted. The CN rules used the fol-
lowing criteria for X4 predictions: (1) R/K at amino acid po-
sition 11 and/or 25 in the V3 loop, (2) a net charge over + 6,
and (3) a net charge over + 5 with R present at amino acid
position 25. Table 1 summarizes all analyzed results in sub-
types B andCRF01_AE as detected byG2P, PSSM, and the CN
rules.
CRF01_AE tropism phenotyping by ESTA and the
pPCR assay
Twelve antiretroviral-naive CRF01_AE samples were ran-
domly selected and sent to Monogram for phenotyping. This
included seven R5 and five D/M viruses that were used to
validate our modified version of the pPCR phenotypic assay.
Our assay managed to reproducibly distinguish between R5
(MJ4, pYU2), X4 (LAIBRU, pNL4-3), and D/M (89.6) reference
strains.More importantly, the assay results completely agreed
with the coreceptor predictions by ESTA. Hence, the pPCR
assay was employed to validate the genotypic tropism tests
for CRF01_AE hereafter.
Based on the CRF01_AE tropism genotypic results, 15
concordant and 22 discordant predictions between each al-
gorithm were selected arbitrarily for evaluation by the pPCR
assay. The sequence alignment of these 37 samples and their
coreceptor predictions by the pPCR assay, G2P, WebPSSM,
and CR are shown in Fig. 1. Individual sensitivities and spe-
cificities of each genotypic algorithm against the ESTA or
pPCR assaywere calculated and are presented in Table 2a and
2b, respectively.
Proposed genotypic analysis guideline for CRF01_AE
As shown in Fig. 1, there were frequent discordant data
observed between G2P andWebPSSM. Our data showed that
using G2P or WebPSSM alone had overidentified X4 in some
patients. This will eliminate the potential CCR5 antagonist
prescription for those patients. After assessing and out-
weighing the sensitivities and specificities of each algorithm,
we propose merging the predictions from G2P (FPR = 10%,
Clonal) andWebPSSM. Sampleswere cidentified asX4 orD/M
only when both algorithms agreed with each other. The
combined predictions were 88.9% sensitive and 89.3% spe-
cific. The prevalence of X4 or D/M in antiretroviral-naive
CRF01_AE-infected patients was estimated to be 39.1% under
these circumstances.
Discussion
To our knowledge, this is the first study focusing on the
CRF01_AE tropism and the prevalence of coreceptor usage
Table 1. Coreceptor Prediction by the G2P and WebPSSM Algorithms and 11/25 and Net Charge Rules
Subtype B (n = 104) Subtype CRF01_AE (n = 87)
Genotypic algorithms R5 (%) X4/DM (%) R5 (%) X4/DM (%) p-valuea
G2P (clonal, FPR 5.75%) 90 (86.5) 14 (13.5) 52 (60.0) 35 (40.2) < 0.0001
G2P (clonal, FPR 10%) 78 (75) 26 (25) 39 (44.8) 48 (55.2) < 0.0001
G2P (clinical, FPR 10%) 89 (85.6) 15 (14.4) 66 (75.9) 21 (24.1) 0.0873
WebPSSM (subtype B x4r5 matrix) 88 (84.6) 16 (15.4) 47 (54.0) 40 (46.0) < 0.0001
11/25 and net charge rules 64 (61.5) 40 (38.5) 71 (81.6) 16 (18.4) 0.0024
aChi-square test.
X4 includes all D/M and X4 predictions; FPR, false-positive rate.
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among antiretroviral-naive patients with current genotypic
and phenotypic assays. The prevalence of X4 or D/M in
subtype B samples is around 10–20% in many validated glo-
bal studies.14,16,37 Depending on the genotypic algorithms, a
similar prevalence at 13.5–25% was observed in our locality.
However, the prevalence of X4 or D/M in CRF01_AE is about
39.1% in Hong Kong, which is slightly lower than other
studies at around 50%.21,23,24 Indeed, the prevalence of X4 or
D/M in CRF01_AE viruses is nearly 2-fold higher than sub-
type B.
In our study, over 50% of CRF01_AE samples with D/M
reported by ESTA had discordant genotypic predictions by
G2P and WebPSSM. Genotypic predictions were based on
population sequencing and considered all possible heteroge-
neous viral populations, yet not all of them were really pres-
ent and able to infect and replicate. More importantly, the env
variable loops 1 and 2 were proposed to affect HIV-1 tro-
pism.38 Our pPCR assay results showed that using G2P or
WebPSSM alone had a high rate of false X4 or D/M predic-
tions for CRF01_AE samples. This implied that the prevalence
of X4 or D/M among CRF01_AE viruses was not as high as
reported.21,22,24,39 The false-positive prediction would be a
concern in the future for patients who have fewer salvage
therapeutic options.
FIG. 1. Thirty-seven antiretroviral-naive patients infected by HIV-1 CRF01_AE were phenotyped by the optimized pPCR
assay. Samples marked with an asterisk (*) were also phenotyped by ESTA for validation. Their genotypic coreceptor
predictions by different algorithms were compared. Discordant predictions by genotyping were shadowed. There were no
distinct polymorphisms associated with the discordant data, as seen in the sequence alignment.
Table 2. Specificities and Sensitivities of the Genotypic Algorithms on CRF01_AE Tropism
2A. True R5 and X4 tropism based on 12 Trofile results
Geno2Pheno
(FPR= 5.75%)
(clonal)
(FPR = 10%)
(clonal)
(FPR= 10%)
(clinical) WebPSSM
Combined 11/25
and net charge
rules
Geno2Pheno
(FPR= 10%, clonal)
and WebPSSM
Specificity 71.4% 71.4% 100% 71.4% 100% 85.7%
Sensitivity 80% 100% 60% 100.0% 80% 100%
2B. True R5 and X4 tropism based on 37 results from the optimized phenotypic assay
Geno2Pheno
(FPR= 5.75%)
(clonal)
(FPR = 10%)
(clonal)
(FPR= 10%)
(clinical) WebPSSM
Combined 11/25
and net charge
rules
Geno2Pheno
(FPR= 10%, clonal)
and WebPSSM
Specificity 71.4% 60.7% 96.4% 78.6% 96.4% 89.3%
Sensitivity 77.8% 88.9% 77.8% 100% 33.3% 88.9%
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The patients recruited for this study were all antiretroviral-
naive and had baseline samples collected at the earliest time
point. A recent study showed that X4 was present in trans-
mission clusters regardless of subtypes and routes of infec-
tion.22 Therefore the evidence of having a high ratio of X4
transmission in CRF01_AE was promising. Some R5-tropic
CRF01_AE isolates in other studies were shown to have a
lower baseline susceptibility than subtype B viruses toward
CCR5 antagonists.40 Thus, an investigation of CRF01_AE
viral pathogenesis will be necessary in the future due to the
high prevalence of X4 observed.
In conclusion, the prevalence of X4 in CRF01_AE
antiretroviral-naive patients is significantly higher than that
in subtype B patients inHongKong. In addition, an optimized
pPCR phenotypic assay, validated with the commercial ESTA
method, was used to evaluate the specificities and sensitivities
of common genotypic coreceptor prediction algorithms on
CRF01_AE variants. Our study proposed a better coreceptor
prediction for CRF01_AE strains by combining G2P (FPR =
10%, Clonal) and WebPSSM (x4r5 subtype B matrix). An in-
dependent study with clinical and virological outcome data
will be required to validate the proposed algorithm before
implementation. The high prevalence of CXCR4 HIV-1 vari-
ants among antiretroviral-naive CRF01_AE patients suggests
the need to evaluate their disease progression and patho-
genesis in future studies.
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